D
ATA FROM ANIMAL studies demonstrate that acute ethanol (EtOH) exposure augments the effects of c-aminobutyric acid (GABA) on the GABA A receptor and inhibits the effects of glutamate on the N-methyl-D-aspartate (NMDA) receptor (Gass and Olive, 2008; Krystal et al., 2006) . Conversely, prolonged EtOH exposure engenders compensatory down-regulation of GABA A receptors and up-regulation of NMDA receptors, culminating in the hypoGABAergic/hyperglutamatergic state of alcohol withdrawal (Gass and Olive, 2008; Krystal et al., 2006) . Although glutamine, the critical amino acid precursor to both glutamate and GABA (Bak et al., 2006) , has rarely been the subject of investigation of preclinical EtOH studies, the available literature suggests increased brain glutamine concentrations in EtOH-fed rats (Lee et al., 2012) and decreased brain glutamine concentrations during acute EtOH withdrawal (Hermann et al., 2012) . Recent advances in proton magnetic resonance spectroscopy ( 1 H-MRS) technology (e.g., increased magnetic field strength, development of spectral editing techniques) have enabled accurate, in vivo measurement of concentrations of glutamate and GABA, as well as glutamine, in human brain tissue.
Notwithstanding a few notable exceptions (e.g., Bauer et al., 2013; Yeo et al., 2013) , when cross-sectional 1 H-MRS investigations of brain glutamate levels in individuals with alcohol use disorder (AUD) are sorted by time since participants' last drink, the literature as a whole demonstrates that brain glutamate levels in individuals with AUD are abnormally high during acute withdrawal (e.g., ≤72 hours) after last alcohol consumption (Hermann et al., 2012) , and abnormally low 1 week after last alcohol consumption (Mon et al., 2012; Thoma et al., 2011) . Short-term follow-up data from 2 studies have additionally demonstrated potential normalization of brain glutamate levels approximately 2 to 5 weeks from last alcohol consumption (Hermann et al., 2012; Mon et al., 2012) . Further, glutamate levels in frontal white matter (WM) were significantly lower in active heavy drinkers who reported a loss of control over their drinking relative to both light and heavy drinkers who did not report loss loss of control over drinking (Ende et al., 2013 (Prescot and Renshaw, 2013) . Nonetheless, while some research has supported decreased GABA (Behar et al., 1999) and increased glutamine (Thoma et al., 2011) in individuals with AUD relative to controls, other studies have failed to replicate these findings (Abe et al., 2013; Mason et al., 2006; Mon et al., 2012) . Although not conducted in individuals with AUD, a recent study of "emerging adults" (aged 18 to 24 years) found significantly decreased anterior cingulate cortex (ACC) GABA levels in binge drinking (with an average of 6 days since their last drink) versus LD participants (Silveri et al., 2014) .
Although the studies discussed above have provided a wealth of information concerning glutamate (and to a lesser extent, GABA and glutamine) disturbances in severe, treatment-seeking individuals with AUD, it is unclear whether and to what degree these disturbances are also present in less severe, treatment-na€ ıve individuals with AUD. The present study was designed to inform this gap in the extant literature by focusing on nonsevere, relatively young (i.e., 21 to 40 years old), non-treatment-seeking individuals with AUD. The present study extends Prisciandaro and colleagues' (2016) finding, which reported a significant inverse correlation between glutamate and recent heavy drinking in treatment-na€ ıve individuals with AUD, through the addition of a demographically matched LD comparator group.
MATERIALS AND METHODS

Overview
The present study used the same methodology, as well as the same sample of AUD participants (with the exception of 1 additional participant that was added to the present sample), as in Prisciandaro and colleagues (2016) , while recruitment of the comparator LD sample temporally overlapped with recruitment of AUD sample, using the same scanner and personnel.
Participants
Twenty individuals with AUD and 20 demographically matched LDs were recruited from community advertisements. All participants were required to be between the ages of 21 and 40. AUD individuals were also required to meet criteria for DSM-IV diagnostic criteria for alcohol dependence (including the "loss of control over drinking" and/or "inability to cut down or stop drinking" criteria) (American Psychiatric Association, 1994) , to report consuming at least 20 total drinks per week, with at least 1 heavy drinking day (i.e., ≥5/4 drinks in a day for men/women) per week, in each of the 2 weeks preceding the study, and to not be actively seeking AUD treatment. LD individuals were required to not meet DSM-IV diagnostic criteria for alcohol dependence, to report drinking fewer than 14 drinks (7 for women) in each of the 2 weeks preceding the study, and to have a negative result (i.e., ≤1.6 IU) for percent disialo carbohydrate-deficient transferrin, a biomarker for recent (past 2-week) heavy drinking (Helander et al., 2016) . For both groups, exclusion criteria included current DSM-IV Axis I disorder other than alcohol dependence or nicotine dependence, positive urine drug or alcohol breath screens on the day of the scan, and/or history of severe alcohol withdrawal (seizure, delirium tremens, need for inpatient or outpatient detoxification), or current alcohol withdrawal symptoms (i.e., Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised [CIWA-Ar (Sullivan et al., 1989) ] >3). Additional magnetic resonance imaging (MRI)-related exclusion criteria included the presence of non-MRI safe objects in the body, claustrophobia, history of traumatic brain injury, or pregnancy.
Procedure
Demographic and diagnostic (via the Structured Clinical Interview for DSM-IV; First 1998) information, along with the Alcohol Dependence Scale (Skinner and Horn, 1984) , was collected. For the current study, participants were administered a breathalyzer, urine drug screen, pregnancy test (females), and 90-day Time-Line Follow-Back (TLFB) interview on the day of the scan (Sobell LC, Sobell MB, 1992) . Participants completed an MRI scan on a 3T Siemens TIM Trio (Erlangen, Germany) including a 2-dimensional Jresolved proton MRS acquisition (2D J-PRESS; TR/TE = 2,400/31 to 229 ms; ΔTE = 2 ms; 4 signal averages per TE step with online averaging; 2D spectral width = 2,000 9 500 Hz; 2D matrix size = 2,048 9 100; total acquisition time for 100 TE steps = 13:28 minutes; Prescot and Renshaw, 2013 ) from a 25 9 25 9 30 mm 3 voxel in the dorsal anterior cingulate cortex (dACC; as per Hermann et al., 2012 ); see Fig. 1 for a sample voxel placement. The dACC was chosen, given its demonstrated role in brain response to alcohol cues, relapse to heavy alcohol drinking, and core neurobehavioral deficits associated with chronic alcoholism (e.g., loss of cognitive control), and because the majority of previous 1 H-MRS studies of AUD have utilized this region (Luijten et al., 2014; Schacht et al., 2013; Zakiniaeiz et al., 2017 ). Water unsuppressed 2D 1 H-MRS data were also acquired from the dACC voxel with 1 signal average recorded for each TE step (total acquisition time for 100 TE steps = 3:28 minutes). A structural scan (magnetization prepared rapid gradient echo (MP-RAGE)) was acquired immediately before 2D J-PRESS in order to facilitate voxel placement and tissue segmentation (TR/TE = 1,900/2.26 ms; FOV = 256 mm 2 ; flip angle = 9°; spatial resolution = 1.0 9 1.0 9 1.0 mm).
H-MRS Postprocessing
Skull stripping and whole brain tissue-type segmentation were performed on MP-RAGE images using the FSL BET and FAST tools (Smith et al., 2004) . In-house MATLAB functions were used to extract the 3D volume corresponding to the positioned MRS voxel to obtain within-voxel gray matter (GM), WM, and cerebrospinal fluid (CSF) tissue content for each subject. Eddy currents and residual water were removed using in-house MATLAB functions. Subsequently, the ProFit algorithm was applied using software-supplied 2D basis sets (Schulte and Boesiger, 2006) . Prior to Fourier transformation, the raw 2D matrix was zero-filled. CramerRao lower bound (CRLB) values, which reflect the uncertainty of estimated model parameters, were provided by the ProFit software. Estimated metabolite peak areas were normalized to the unsuppressed water signal. Finally, metabolite/water ratios were corrected for within-voxel CSF fraction (Prescot and Renshaw, 2013) .
Analytic Plan
Following characterization of demographic and clinical variables between groups, separate general linear models were evaluated for glutamate, glutamine, and GABA, with group (AUD vs. LD) included as the sole modeled between-subjects factor. Although our hypotheses concerned glutamate, glutamine, and GABA, we estimated supplementary models for the remaining estimable metabolites (NAA, choline, creatine, and myo-inositol) for completeness. Within-voxel GM tissue fraction, expressed as the ratio of GM to brain matter (i.e., GM + WM), was entered as a covariate in each model to adjust coefficients for individual differences in within-voxel tissue composition. Following these analyses, correlations were estimated between metabolite levels and TLFB-derived drinking variables (e.g., number of drinking days, number of heavy drinking days; past 14-day recall window). Alpha was set conservatively (i.e., given nonindependence of dependent variables, mean r = 0.40) to p = 0.017 for primary comparisons of interest (i.e., between-group differences in glutamate, glutamine, and GABA; p = 0.05/3). Alpha was set to p < 0.05, uncorrected, for all additional analyses.
RESULTS
See Table 1 for demographic and alcohol use characteristics of the sample. AUD and LD participants did not significantly differ on any demographic variable, but, as expected, differed significantly on alcohol use characteristics (i.e., Alcohol Dependence Scale scores, number of heavy drinking days, and drinks per drinking day, but not number of days since last drinking day). AUD participants reported an average of 2.45 (SD = 1.23, range ≤1 to 5) days since their last drinking day. CRLBs for metabolite concentration estimates were <20% (M glutamate CRLB = 1.44%, M GABA CRLB = 6.56%, M glutamine CRLB = 6.36%), with the exception of 1 AUD participant with a glutamine CRLB of 21.58%. Raw, Voigt-fit water integrals did not differ between AUD and LD groups (t = 1.41, p = 0.166). There was a significant difference in average within-voxel GM to brain matter tissue fraction (i.e., GM/[GM/WM]) between AUD (61.08%) and LD (64.59%; t [38] = 4.49, p < 0.001).
See Table 2 for general linear model results. GM to brain matter proportion was not significantly associated with metabolite concentrations in any of the general linear models (mean p = 0.35). Although not significantly different between groups, there was a trend toward differences in Fig. 1 . Sample ACC voxel location (right) and raw (top) and fitted (bottom) 2-dimensional J-resolved 1H-MRS spectra analyzed using prior knowledge fitting (ProFit). Colored horizontal bars represent approximate primary spectral locations of Glu, GABA, and Gln. Gln = glutamine, Glu = glutamate, GABA = c-aminobutyric acid, NAA = N-acetylaspartate, Cre = creatine, Cho = choline. education between AUD and LD participants (p = 0.085), so we additionally evaluated education as a potential covariate across models. Education was not significantly associated with metabolite concentrations in any of the general linear models (mean p = 0.81). Final models were estimated without GM to brain matter proportion or education included as covariates, and results did not change substantively from their removal. As detailed in Table 2 , levels of GABA and glutamine, but not other metabolites, were significantly different between AUD and LD participants. Specifically, GABA (Cohen's d = 0.79) and glutamine levels (Cohen's d = 1.12) were significantly lower in AUD relative to LD participants.
As reported in Prisciandaro and colleagues (2016) , number of heavy drinking days in the preceding 14 days was significantly inversely associated with glutamate (r = À0.55, p = 0.012) and NAA concentrations (r = À0.51, p = 0.022) in AUD participants (coefficients and p-values updated here to reflect the present, n + 1, AUD sample). Conversely, neither number of heavy drinking days (mean p = 0.47, all correlations negative) nor number of drinking days (mean p = 0.56, all correlations negative) was significantly associated with concentrations of any of the measured metabolites in LD participants.
DISCUSSION
The present study demonstrated significantly lower dACC GABA and glutamine levels in actively drinking, treatmentna€ ıve individuals with AUD relative to demographically matched LD, with each group reporting an average of approximately 2.5 days since their last drink. As published in Prisciandaro and colleagues (2016) , dACC glutamate, but not GABA or glutamine, levels were inversely correlated with number of recent heavy drinking days in the present sample of AUD individuals. As an extension of that study, the present study found no correlation between recent drinking and levels of any of the measured neurometabolites in LD.
Most prior 1 H-MRS studies of AUD have focused on more severe, treatment-seeking individuals reporting >1 week of abstinence from alcohol and have found decreased levels of prefrontal glutamate relative to controls. Investigations of individuals with <1 week of abstinence have been relatively rare, presumably due to the physiological instability and need for GABA/glutamate-altering (e.g., benzodiazepine) treatments associated with acute alcohol withdrawal. Indeed, the only published 1 H-MRS study of acute alcohol withdrawal in AUD demonstrated large, transient elevations in prefrontal glutamate that would be expected to accompany alcohol withdrawal symptoms (e.g., autonomic hyperarousal; Hermann et al., 2012) . In contrast, by focusing on lower severity, frequent heavy episodic drinkers, 2 additional 1 H-MRS studies have characterized glutamate and GABA levels, respectively, in drinkers with <1 week of abstinence who did not have clinically significant alcohol withdrawal symptoms. Consistent with the present study, Silveri and colleagues (2014) reported lower levels of dACC GABA in 18-to 24-year-old binge drinkers relative to LDs, along with associations between ACC GABA and cognitive measures of response inhibition and attention; there were no between-group differences in ACC glutamate. Demonstration of significantly lower ACC GABA levels in recently drinking AUD individuals is consistent with the well-known compensatory down-regulation of GABA A receptors following prolonged EtOH exposure, as well as results from a study that found decreased occipital GABA levels in response to an acute intravenous alcohol challenge 1 H-MRS (Gomez et al., 2012) . As reported by Silveri and colleagues, low ACC GABA levels in this population are particularly concerning as they have been linked with greater alcohol use consequences and worse response inhibition and mental flexibility in chronic heavy drinkers (Silveri et al., 2014) .
In contrast to the absence of observed differences in prefrontal glutamate levels between AUD and LD from the present study, Ende and colleagues (2013) found that heavy drinkers who reported loss of control over their drinking had significantly lower levels of frontal WM glutamate than did heavy drinkers reporting no loss of control or LDs. Several factors may account for differences between Ende and colleagues' (2013) results and the present study. First, participants in Ende and colleagues' (2013) study were substantially older than were participants in the present study (M age = 49 years vs. 27 years). Furthermore, the heavy drinking participants in Ende and colleagues' (2013) sample reported drinking, on average, far more heavily than the AUD participants in the present study (i.e., approximately 75% of recent days classified as heavy drinking days vs. approximately 35% in the present study). This speculative explanation is consistent with Prisciandaro and colleagues' (2016) finding that AUD participants with a greater number of recent heavy drinking days had significantly lower levels of ACC glutamate relative to participants with fewer recent heavy drinking days.
Neither Silveri and colleagues (2014) nor Ende and colleagues (2013) reported participants' brain glutamine levels, as reliably measuring glutamine in vivo requires specialized 1 H-MRS acquisition sequences, such as the 2D J-PRESS sequence used in the present study. Nonetheless, 1 previous study reported significantly higher dACC levels of glutamine, in a combined sample of AUD individuals with active (n = 7) or remitted (n = 6) drinking (many of whom were diagnosed with a variety of psychiatric disorders) relative to controls, using a standard PRESS acquisition sequence (Thoma et al., 2011) . In contrast, the present study found evidence for significantly lower levels of dACC glutamine in AUD relative to LD participants. Given that glutamine acts as a metabolic precursor to both glutamate and GABA, the present study's finding of significantly lower glutamine levels is consistent with its corollary finding of significantly lower GABA levels in AUD, as well as lower glutamate levels in AUD reporting a greater number of recent heavy drinking days. Differences in 1 H-MRS acquisition may account for the difference between these findings and Thoma and colleagues' (2011) results.
Due to the cross-sectional design of the present study, and most of the associated literature, what is most needed at this time are longitudinal studies designed to elucidate the interrelated dynamics of brain glutamate, GABA, and glutamine levels in individuals with AUD. Given the dearth of longitudinal 1 H-MRS studies in individuals with AUD, it remains controversial whether the oft-observed neurochemical disturbances result from the acute neurotoxic consequences of, and/or neuroadaptive response to, heavy drinking on the brain and, if so, to what degree these disturbances normalize across periods of abstinence. Since evaluation of neurometabolism in nonabstinent individuals with severe AUD is greatly complicated by the acute, excitotoxic effects of alcohol withdrawal, or alternatively the acute, inhibitory effects of alcohol consumption/ intoxication, it may prove fruitful to evaluate trajectories of neurochemical disturbances in nonabstinent individuals with less severe AUD, who do not experience clinically significant alcohol withdrawal symptoms upon ceasing alcohol intake. In any case, it is very important that 1 H-MRS studies of AUD provide detailed descriptions of recent drinking levels and abstinence times in order to compare results across studies.
The results of the present study should be interpreted in light of several limitations. First, the study included a relatively modest-sized sample of AUD participants. Results should therefore be considered tentative until replicated. Second, the recent drinking variable relied entirely on subjective self-report; supplementation of subjective drinking data with objective biomarkers of recent alcohol consumption would strengthen confidence in our findings. Third, the present analytic methods available for our 2D J-PRESS 1 H-MRS sequence did not allow for separation of co-edited macromolecules from the observed GABA signal. Fourth, because assessment for the present study was limited and the sample was selected to be homogeneous on a number of key alcohol diagnostic and drinking variables, we were not able to evaluate correlations between metabolite concentrations and additional clinically meaningful variables (e.g., age of onset). Fifth, as noted above, the cross-sectional design of the present study substantially limited the potential interpretability of findings. Sixth, the present study was not adequately powered to examine potential sex differences and did not include assessment of menstrual cycle phase in females. This is potentially problematic because females with a natural menstrual cycle (e.g., who are not taking hormonal contraceptives) have been shown to have small but significant variation in prefrontal GABA levels across menstrual cycle phases (de Bondt et al., 2015) . Seventh, we cannot comment on the regional specificity of our findings given that we did not acquire data from brain regions other than ACC. Finally, we were unable to examine potential associations between blackout history and metabolite concentrations in AUD participants.
These limitations notwithstanding, the present study extends the literature by demonstrating significantly lower dACC GABA and glutamine levels in a sample of relatively young and less severe, non-treatment-seeking individuals with AUD. If these results are replicated, this could lead to enhanced knowledge of how the GABA and glutamate systems change with drinking and could lead to pharmacological interventional/preventative strategies, as well as allowing identification of groups at risk for accelerated AUD symptoms based on genetic or other demographic/diagnostic differences. The ability of MRS techniques to link brain neurochemistry to knowledge in other areas warrants further exploration.
